Knight Therapeutics Inc (CVE:GUD) had its price target dropped by equities research analysts at National Bank Financial from C$10.75 to C$10.50 in a report released on Monday. The brokerage presently has an “outperform” rating on the specialty pharmaceutical company’s stock. National Bank Financial’s price target would suggest a potential upside of 71.01% from the company’s previous close.
Knight Therapeutics (GUD) opened at C$6.14 on Monday. Knight Therapeutics has a 1-year low of C$3.51 and a 1-year high of C$7.24.
TRADEMARK VIOLATION WARNING: This report was published by Stock Observer and is the property of of Stock Observer. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.thestockobserver.com/2017/11/15/knight-therapeutics-inc-gud-pt-lowered-to-c10-50.html.
Knight Therapeutics Company Profile
Knight Therapeutics Inc, a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally. The companys commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement.
Receive News & Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.